ClinicalTrials.gg
Not yet recruitingNCT07937696Updated Nov 16, 2026

A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome

A Phase 2 interventional study of Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP and Biopsy Procedure in Colorectal Carcinoma, EPCAM Lynch Syndrome and Lynch Syndrome, sponsored by National Cancer Institute (NCI). Not yet recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionColorectal Neoplasms, Hereditary NonpolyposisRegistry: Colorectal NeoplasmsReclassifiedWhy we changed it
Registry
Colorectal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colorectal Neoplasms, Hereditary Nonpolyposis
Why
  1. The study's listed conditions name Colorectal Neoplasms, Hereditary Nonpolyposis, a narrower term within Colorectal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Prevention

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States — 21 open to participants now, 33 under way, 2 of them phase 3. Colorectal Neoplasms, Hereditary Nonpolyposis · United States.

Planned enrollment
30th of 43
55 · median 162
Started
2027
the only one that year
Phase 2
6 of 72
3 open now
Primary completion
2031-11
later than 27 of 32 live
Registered
72nd of 72
by date
Lead sponsor
8 of 72
National Cancer Institute (NCI)

Among the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, this one is the 30th largest by planned enrollment of the 43 interventional ones that give a count, is the only one that started in 2027, is one of 6 in phase 2, reaches primary completion later than 27 of the 32 other live ones, and was the 72nd registered.

Colorectal Neoplasms, Hereditary Nonpolyposis

147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 60 are open to participants now.

Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →

Open to participants now

21 of the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Colorectal Neoplasms, Hereditary Nonpolyposis studies recruiting now, 32 (74%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, or all of them as a file.
02

Study summary

This phase II trial studies how well a vaccine called Nous-209 works in reducing the size of abnormal area of tissue growth or polyps (colorectal lesions) in patients with Lynch syndrome. When patients have Lynch syndrome, errors in the genetic information inside cells are not properly corrected. When that happens, the cells produce new proteins called neoantigens. Nous-209 is a vaccine with man-made copies of neoantigens combined with viral vectors. Neoantigens are new proteins that form inside tumor cells when certain mutations occur inside them. The body's immune system recognizes these proteins as foreign and generates a response against the tumor cell that produced the neoantigen. Giving the Nous-209 vaccine may be able to reduce the size of existing colorectal lesions (polyps) that were 5 to 15 mm in diameter at the time of patients' first colonoscopy or flexible sigmoidoscopy.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess the effect of adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP and modified vaccinia Ankara virus (MVA) tumor-specific neoantigen boosting vaccine MVA-209-FSP (Nous-209) on the participant-level response rate based on the change from baseline to week 16 in the size of qualified colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm in diameter detected at the baseline lower gastrointestinal (GI) endoscopy (change of the cumulative size of lesions per trial participant).

SECONDARY OBJECTIVES:

I. To assess the effect of Nous-209 on the change in the size of colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm in diameter detected at the baseline lower GI endoscopy to week 16, regardless of mismatch repair (MMR) status (analysis of all lesions observed in the study within this size range).

II. To assess the development of new lesions during the treatment period defined as lesions identified at week 16 that were not observed at the baseline lower GI endoscopy (incidence of new lesions at week 16).

III. To assess the development of new lesions defined as lesions identified at month 16 that were not observed at the lower GI endoscopy at week 16 (incidence of new lesions at month 16).

IV. To assess the effect of Nous-209 on the change in the size of colorectal lesions that are less than 5 mm and greater than 15 mm in diameter detected at week 16 and at month 16 lower GI endoscopy.

V. To assess the safety of Nous-209 in the clinical trial participants for the duration of the study (16 months).

VI. To evaluate the immunogenicity of Nous-209 post-vaccination using enzyme-linked immunosorbent spot assay (ELISpot) and other immunological assays in trial participants at week 16 and at month 16.

EXPLORATORY OBJECTIVES:

I. To assess the effect of Nous-209 on the change in the size of mismatch repair deficient (MMRd) colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm in diameter detected at the baseline lower GI endoscopy to week 16 determined by immunohistochemistry (IHC) performed in the biopsy/resection tissue obtained at end-of-study lower GI endoscopy (analysis of MMRd lesions only).

II. To assess changes post- versus (vs) pre-vaccination of levels of T cell infiltration, T cell immune-profile, T cell receptor (TCR) repertoire, and pathological features including presence/absence of dysplasia in colorectal lesions (for the entire duration of the trial).

III. To assess changes in peripheral blood T cell immune-profile and TCR repertoire induced by vaccination with Nous-209 in trial participants (for the entire duration of the trial).

IV. To assess changes post- vs pre-vaccination of levels of T cell infiltration, T cell immune-profile, TCR repertoire, and pathological features in normal colorectal mucosal biopsies adjacent to detected colorectal lesions (for the entire duration of the trial).

V. To assess vaccine-induced T-cell cytotoxicity on matched patient-derived colorectal lesions and normal mucosa organoids (for the entire duration of the trial).

OUTLINE:

Patients receive adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP (GAd20-209-FSP) intramuscularly (IM) at week 0 (day 1) followed by MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP (MVA-209-FSP) IM at week 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo colonoscopy or flexible sigmoidoscopy, tissue biopsies, and blood sample collection throughout the study.

After completion of study intervention, patients are followed up at weeks 9 and 16, and then months 8, 12, and 16.

03

Conditions studied

  • Colorectal Carcinoma
  • EPCAM Lynch Syndrome
  • Lynch Syndrome
  • MLH1 Lynch Syndrome
  • MSH2 Lynch Syndrome
  • MSH6 Lynch Syndrome
  • PMS2 Lynch Syndrome

Browse trials for

04

In context

Colorectal Neoplasms, Hereditary Nonpolyposis Reclassified

147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 60 are open to participants now.

This study's planned enrollment of 55 is below the median of 200 across 76 interventional studies indexed under Colorectal Neoplasms, Hereditary Nonpolyposis.

Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 336 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Compared within Colorectal Neoplasms, Hereditary Nonpolyposis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Colorectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 years or older
  • Participants must be diagnosed with Lynch syndrome. They must be documented carriers (or obligate carriers by pedigree) of a germline mutation in MMR genes (MLH1, MSH2/EPCAM, MSH6, or PMS2) that is deleterious/pathogenic or suspected to be deleterious/pathogenic (known or predicted to be detrimental/loss of function, respectively). The mutation must have been identified through a Clinical Laboratory Improvement Act (CLIA)-approved laboratory setting or an equivalent international agency. Final determination of eligibility for any discordant results in pathogenicity of the mutation will be determined by the study investigator. A formal eligibility exception in those instances will not be required as long as approval by the overall study principal investigator (PI) has been granted and documented
  • Participants must have at least one colorectal lesion that is greater than or equal to 5 mm to less than or equal to 15 mm in diameter (including lesions measuring exactly 5 mm or 15 mm) and narrow-band imaging (NBI) international colorectal endoscopic (NICE) Type II identified during the baseline lower GI endoscopy
  • Participants must have documented history of tubular adenomas and/or tubulovillous adenomas and/or advanced adenomas in the previous five years
  • Participants must have no evidence of active or recurrent invasive cancer for 6 months prior to screening
  • Participants must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy, or radiation)
  • Participants must have endoscopically accessible distal colon and/or rectal mucosa (i.e., participants must have at least part of the descending/sigmoid colon and/or rectum intact)
  • Participants must consent to a follow-up lower GI endoscopy with 4 months after their initial study lower GI endoscopy
  • Participants must consent to refrain from using aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase (COX) inhibitors for the duration of the trial, except for cardiopreventive aspirin (less than or equal to 100 mg daily). Individuals taking such drugs may not be enrolled unless they are willing to stop the medications (and possibly change to alternative non-excluded medications to treat the same conditions) no less than 1 month prior to enrollment. Participants will discuss with their primary care provider/local provider about the discontinuation of such medication(s) and obtain approval prior to stopping any agent
  • (ECOG) performance status less than or equal to 1 ( greater than or equal to 70%)
  • greater than or equal to 10 g/dL or hematocrit greater than or equal to 30% (obtained within 30 days of study enrollment)
  • Leukocyte count greater than or equal to 3,500/microliter (obtained within 30 days of study enrollment)
  • count greater than or equal to 100,000/microliter (obtained within 30 days of study enrollment)
  • greater than or equal to 1,500/microliter (obtained within 30 days of study enrollment)
  • Estimated (eGFR) (or calculated using the Cockcroft-Gault equation) greater than or equal to 60 mL/min/1.73m\^2 (mL/min, within institutional limits of normal) (obtained within 30 days of study enrollment)
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) less than or equal to 2 times the institutional (ULN) (obtained within 30 days of study enrollment)
  • Total less than or equal to 1.5 the ULN (obtained within 30 days of study enrollment); participants with Gilbert's disease may be enrolled with higher total bilirubin if their direct bilirubin is less than or equal to 1.5 times the ULN
  • Participants must consent to refrain from receiving adenoviral-based vaccines for the duration of the trial (16 months)
  • Participants must consent to refrain from receiving any other type of vaccination during the first 10 weeks of the trial
  • Willing and able to adhere to the prohibitions and restrictions specified in the final approved protocol
  • The effects of Nous-209 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry for the duration of study participation (16 months) and 6 months after end of study. Additionally, men who are Lynch syndrome (LS) carriers must not donate sperm for the purpose of reproduction either during the study or after the study, so as not to pass on the risk of inheriting the pathogenic gene variant to the offspring. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
  • Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Prior receipt of a recombinant adenoviral or MVA vaccine, including coronavirus disease 2019 (COVID-19) adenovirus vaccines
  • Individuals with active extra-colonic (excluding non-melanoma skin cancer)
  • Individuals with a colonic lesion larger than 15 mm with high grade dysplasia/malignancy at the time of the baseline lower GI endoscopy
  • Any serious uncontrolled and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with participant's safety, obtaining , or compliance to the study procedures
  • Active infection (acute and self-limited) or (HIV), virus (HBV), or virus (HCV) infection. Participants with laboratory evidence of cleared HBV and HCV infection will be permitted
  • History of organ allograft or other history of immunodeficiency
  • Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to study drug, or , or to egg proteins
  • Individuals with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications (such as infliximab, rituximab, adalimumab, tacrolimus) within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active disease
  • Pregnant or breastfeeding or planning to become pregnant within 6 months after the end of study. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with Nous-209, breastfeeding should be discontinued if the mother is treated with Nous-209
  • Men attempting or planning to conceive children during the study or within 6 months after the end of the study
  • Participants who are receiving any other agents
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Prevention (Nous-209)

    Patients receive GAd20-209-FSP IM at week 0 (day 1) followed by MVA-209-FSP IM at week 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo colonoscopy or flexible sigmoidoscopy, tissue biopsies, and blood sample collection throughout the study.

    Biological: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Colonoscopy · Biological: MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP · Procedure: Sigmoidoscopy

Interventions

  • Given IM

    Also known as: GAd-209-FSP, GAd20-209-FSP, Great Ape Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP

  • ProcedureBiopsy Procedure

    Undergo tissue biopsies

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureColonoscopy

    Undergo colonoscopy

  • BiologicalMVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP

    Given IM

    Also known as: Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, MVA-209-FSP

  • ProcedureSigmoidoscopy

    Undergo flexible sigmoidoscopy

    Also known as: Proctosigmoidoscopy

07

What researchers measure

Primary outcomes

  1. Participant-level response rate

    Will be based on the change from baseline to week 16 in the size of colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm in diameter detected at the baseline lower gastrointestinal (GI) endoscopy (change of the cumulative size of lesions per trial participant). The participant-level response rate will be estimated along with its one-sided 95% confidence interval, which will be constructed assuming the exact binomial distribution. All primary analyses will be conducted at the participant level. New lesions detected at week 16 will be included in the primary endpoint analysis. When calculating the change in cumulative lesion diameter from baseline to week 16, the baseline diameter of a new lesion detected at Week 16 would be considered zero.

    Time frame: Baseline to week 16

Secondary outcomes

  1. Change in the size of colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm, regardless of mismatch repair (MMR) status

    Will be evaluated using mixed-effects models, with participant included as a random effect to account for correlation among multiple lesions within the same participant. Analyses of MMR deficient (MMRd) lesions will be conducted similarly among lesions with available MMR status.

    Time frame: Baseline to week 16

  2. Development of new colorectal lesions

    Defined as lesions identified at week 16 that were not observed at the baseline lower GI endoscopy (incidence of new lesions at week 16). Will be summarized by the number and percentage of participants with at least one new lesion.

    Time frame: Baseline to week 16

  3. Development of new colorectal lesions

    Defined as lesions identified at month 16 that were not observed at the baseline lower GI endoscopy (incidence of new lesions at month 16). Will be summarized by the number and percentage of participants with at least one new lesion.

    Time frame: Baseline to month 16

  4. Change in the size of colorectal lesions that are < 5 mm and > 15 mm in diameter

    Will be evaluated using mixed-effects models, with participant included as a random effect to account for correlation among multiple lesions within the same participant. Analyses of MMRd lesions will be conducted similarly among lesions with available MMR status.

    Time frame: Baseline up to month 16

  5. Incidence and severity of adverse events

    Safety endpoints will be summarized in tabular format by type, severity, and attribution. Safety endpoints will be summarized by frequency and percentage, including rates of grade 2/3 adverse events and grade 2-5 adverse events.

    Time frame: Up to 16 months

  6. Immunogenicity of Nous-209

    Will be evaluated using enzyme-linked immunosorbent spot assay and other immunological assays.

    Time frame: Baseline up to 16 months

Other outcomes

  1. Change in the size of MMRd colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm in diameter

    Assessed in lesions detected at the baseline lower GI endoscopy determined by immunohistochemistry performed in the biopsy/resection tissue obtained at end-of-study lower GI endoscopy (analysis of MMRd lesions only).

    Time frame: Baseline up to month 16

  2. Changes of levels of T cell infiltration, T cell immune-profile, T cell receptor (TCR) repertoire, and pathological features

    Will assess changes post- versus pre-vaccination of levels of T cell infiltration, T cell immune-profile, TCR repertoire, and pathological features including presence/absence of dysplasia in colorectal lesions (for the entire duration of the trial). Will be analyzed descriptively. Changes over time will be evaluated using the longitudinal modeling, as appropriate.

    Time frame: Baseline up to month 16

  3. Changes in peripheral blood T cell immune-profile and TCR repertoire induced by vaccination with Nous-209

    Will be analyzed descriptively. Changes over time will be evaluated using the longitudinal modeling, as appropriate.

    Time frame: Baseline up to month 16

  4. Changes of levels of T cell infiltration, T cell immune-profile, TCR repertoire, and pathological features in normal colorectal mucosal biopsies adjacent to detected colorectal lesions

    Will be analyzed descriptively. Changes over time will be evaluated using the longitudinal modeling, as appropriate.

    Time frame: Baseline up to month 16

  5. Vaccine-induced T-cell cytotoxicity on matched patient-derived colorectal adenoma and normal mucosa organoids

    Will be analyzed descriptively. Changes over time will be evaluated using the longitudinal modeling, as appropriate.

    Time frame: Baseline up to month 16

08

Study locations

5 sites
09

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2027; primary completion for Nov 2031, 55 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 16, 2026
StartEst.
Apr 27, 2027
Primary completionEst.
Nov 30, 2031
CompletionEst.
Jul 31, 2032
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07937696
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Apr 27, 2027 (estimated)
Primary completion
Nov 30, 2031 (estimated)
Completion
Jul 31, 2032 (estimated)
Last update
Nov 16, 2026

Study contacts

Eduardo Vilar-Sanchez
principal investigator · UT MD Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP

Start the discussion